Currently, of the various drugs developed for the targeted therapy of human cancers, the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), cetuximab and panitumumab, and the anti-vascular endothelial growth factor (VEGF) mAb bevacizumab have been incorporated into treatment paradigms for the majority of patients with metastatic colorectal cancer [2]–[5]. This evidence concerns the gene EGFR and metastatic colorectal cancer.